Study of miR-1 Blood Levels as a Biomarker to Track Muscular Dystrophies and Congenital Myopathies

What this Trial Is About

Researchers are investigating whether a specific blood molecule called miR-1 can serve as a biomarker to monitor the health and progression of certain muscle diseases. This study focuses on patients with Duchenne or Becker muscular dystrophy, Myotonic Dystrophy Type 1 Steinerts disease, congenital myopathies, and healthy volunteers as a comparison group. The goal is to better understand how miR-1 levels relate to disease severity and progression. Participants will provide a single blood sample to measure the level of miR-1 in their blood. This diagnostic test is done once at enrollment to compare miR-1 levels across the different groups and disease types. No other interventions or treatments are part of the study. During the study, participants will undergo demographic and severity assessments at the time of their blood draw. Researchers will analyze the blood expression level of miR-1 and its correlation with the participants age and disease severity. The study will continue until March 2029, and participants are involved only for the single blood sampling visit.

Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies